These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36821375)

  • 1. Therapeutic potential of convalescent plasma and hyperimmune immunoglobulins against SARS-CoV-2 BQ.1, BQ.1.1, and XBB variants.
    Bellusci L; Golding H; Khurana S
    J Clin Invest; 2023 Apr; 133(8):. PubMed ID: 36821375
    [No Abstract]   [Full Text] [Related]  

  • 2. Potential use of convalescent plasma for SARS-CoV-2 prophylaxis and treatment in immunocompromised and vulnerable populations.
    Focosi D; Franchini M
    Expert Rev Vaccines; 2022 Jul; 21(7):877-884. PubMed ID: 34015243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralisation of circulating SARS-CoV-2 delta and omicron variants by convalescent plasma and SARS-CoV-2 hyperimmune intravenous human immunoglobulins for treatment of COVID-19.
    Zahra FT; Bellusci L; Grubbs G; Golding H; Khurana S
    Ann Rheum Dis; 2022 Jul; 81(7):1044-1045. PubMed ID: 35144925
    [No Abstract]   [Full Text] [Related]  

  • 4. Development and characterization of anti-SARS-CoV-2 intravenous immunoglobulin from COVID-19 convalescent plasma.
    Razumikhin M; Smolyanova T; Nikolaeva A; Orlova E; Ivanov A; Belyakova O; Vyaznikova T; Selezneva N; Perevozchikov A; Sokolova A; Zubkova N; Efimova I; Dolzhikova I; Logunov D; Sakanjan E
    Immunotherapy; 2022 Oct; 14(14):1133-1147. PubMed ID: 35892311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thinking more about therapy with convalescent plasma for COVID-19 patients.
    Han G; Zhou YH
    Hum Vaccin Immunother; 2020 Nov; 16(11):2601-2603. PubMed ID: 32643512
    [No Abstract]   [Full Text] [Related]  

  • 6. Production of hyperimmune anti-SARS-CoV-2 intravenous immunoglobulin from pooled COVID-19 convalescent plasma.
    Ali S; Uddin SM; Ali A; Anjum F; Ali R; Shalim E; Khan M; Ahmed I; M Muhaymin S; Bukhari U; Luxmi S; Khan AS; Quraishy S
    Immunotherapy; 2021 Apr; 13(5):397-407. PubMed ID: 33557591
    [No Abstract]   [Full Text] [Related]  

  • 7. Validation of Viral Inactivation Protocols for Therapeutic Blood Products against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-COV-2).
    Belem WF; Liu CH; Hu YT; Burnouf T; Lin LT
    Viruses; 2022 Oct; 14(11):. PubMed ID: 36366517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How should we use convalescent plasma therapies for the management of COVID-19?
    Wood EM; Estcourt LJ; McQuilten ZK
    Blood; 2021 Mar; 137(12):1573-1581. PubMed ID: 33202419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Production and Quality Assurance of Human Polyclonal Hyperimmune Immunoglobulins Against SARS-CoV-2.
    Burnouf T; Gathof B; Bloch EM; Bazin R; de Angelis V; Patidar GK; Rastvorceva RMG; Oreh A; Goel R; Rahimi-Levene N; Hindawi S; Al-Riyami AZ; So-Osman C;
    Transfus Med Rev; 2022 Jul; 36(3):125-132. PubMed ID: 35879213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Highly Potent SARS-CoV-2 Neutralization by Intravenous Immunoglobulins manufactured from Post-COVID-19 and COVID-19-Vaccinated Plasma Donations.
    Karbiener M; Farcet MR; Schwaiger J; Powers N; Lenart J; Stewart JM; Tallman H; Kreil TR
    J Infect Dis; 2021 Nov; 224(10):1707-1711. PubMed ID: 34543421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin.
    Volk A; Covini-Souris C; Kuehnel D; De Mey C; Römisch J; Schmidt T
    BioDrugs; 2022 Jan; 36(1):41-53. PubMed ID: 34843105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pan-sarbecovirus vaccine based on RBD of SARS-CoV-2 original strain elicits potent neutralizing antibodies against XBB in non-human primates.
    Liu Z; Zhou J; Wang X; Xu W; Teng Z; Chen H; Chen M; Zhang G; Wang Y; Huang J; Wang Q; Jiang S; Lu L
    Proc Natl Acad Sci U S A; 2023 Mar; 120(11):e2221713120. PubMed ID: 36897979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On the Need to Determine the Contribution of Anti-Nucleocapsid Antibodies as Potential Contributors to COVID-19 Convalescent Plasma Efficacy.
    Focosi D; Franchini M; Casadevall A
    Viruses; 2022 Oct; 14(11):. PubMed ID: 36366476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamics of anti-SARS-CoV-2 antibodies in repeat convalescent plasma donors.
    Franchini M; Glingani C; Liumbruno GM; Mengoli C
    Transfus Apher Sci; 2021 Dec; 60(6):103216. PubMed ID: 34315677
    [No Abstract]   [Full Text] [Related]  

  • 15. Convalescent plasma to deliver therapeutic antibodies against COVID-19.
    Senefeld JW; Casadevall A; Joyner MJ
    Trends Mol Med; 2022 May; 28(5):435-436. PubMed ID: 35248476
    [No Abstract]   [Full Text] [Related]  

  • 16. Locally harvested Covid-19 convalescent plasma could probably help combat the geographically determined SARS-CoV-2 viral variants.
    Raturi M; Kusum A; Kala M; Mittal G; Sharma A; Bansal N
    Transfus Clin Biol; 2021 Aug; 28(3):300-302. PubMed ID: 33971318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stability and neutralising capacity of SARS-CoV-2-specific antibodies in convalescent plasma.
    Tonn T; Corman VM; Johnsen M; Richter A; Rodionov RN; Drosten C; Bornstein SR
    Lancet Microbe; 2020 Jun; 1(2):e63. PubMed ID: 32835332
    [No Abstract]   [Full Text] [Related]  

  • 18. Low neutralization capacity against SARS-CoV-2 Omicron BQ.1.1 of convalescent plasma collected during circulation of Omicron BA.1.
    Gallian P; Brisbarre N; Nurtop E; Le Cam S; Franck T; Isnard C; Malard L; Laperche S; Richard P; Morel P; Tiberghien P; de Lamballerie X
    Vox Sang; 2023 May; 118(5):407-408. PubMed ID: 36897221
    [No Abstract]   [Full Text] [Related]  

  • 19. High-Dose Convalescent Plasma for Treatment of Severe COVID-19 (response).
    De Santis GC; Calado RT
    Emerg Infect Dis; 2022 May; 28(5):1083-1084. PubMed ID: 35447061
    [No Abstract]   [Full Text] [Related]  

  • 20. Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma.
    Vandeberg P; Cruz M; Diez JM; Merritt WK; Santos B; Trukawinski S; Wellhouse A; Jose M; Willis T
    Transfusion; 2021 Jun; 61(6):1705-1709. PubMed ID: 33715160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.